Northwire Canada EditionSaturday, October 17, 2026
Sign inSubscribe
Northwire
⌕
GOLD 4181.10 +0.3% SILVER 57.30 +0.3% COPPER 6.57 +0.3% OIL 99.02 +1.1% PALLADIUM 1118.60 −0.9% GBU 0.095 +0.0% ATY 0.225 +4.7% GRDM 0.215 +0.0% PPM 0.300 +0.0% GZD 0.040 −11.1% CAN 0.060 +0.0% BGF 0.025 +0.0% MSV 0.570 +0.0% CCMM 0.485 +0.0% MON 0.385 −6.1% OMI 0.245 −2.0% BUFF 0.800 +2.6% FEO 0.630 −3.1% LIB 0.710 −1.4% NPR 0.620 +0.0% QZM 0.380 +0.0% GOLD 4181.10 +0.3% SILVER 57.30 +0.3% COPPER 6.57 +0.3% OIL 99.02 +1.1% PALLADIUM 1118.60 −0.9% GBU 0.095 +0.0% ATY 0.225 +4.7% GRDM 0.215 +0.0% PPM 0.300 +0.0% GZD 0.040 −11.1% CAN 0.060 +0.0% BGF 0.025 +0.0% MSV 0.570 +0.0% CCMM 0.485 +0.0% MON 0.385 −6.1% OMI 0.245 −2.0% BUFF 0.800 +2.6% FEO 0.630 −3.1% LIB 0.710 −1.4% NPR 0.620 +0.0% QZM 0.380 +0.0%
Financings

Kane Biotech Announces Closing of Private Placement Offering with an Insider of the Company

By The Northwire Desk — AI Analysis Dec 18, 2025 · 07:25 KNE · 0.03 Kane Biotech Inc.
KNE · Price

Executive Summary

  • Kane Biotech completed a non‑brokered private placement of 14 million common shares at $0.05 per share, generating gross proceeds of $700,000.
  • All shares were sold to an insider; net proceeds will be used for working capital and general corporate purposes.
  • The transaction is classified as a related‑party transaction but is exempt from formal valuation and minority‑approval requirements under MI 61‑101.

Key Details

  • Offering Size: 14,000,000 common shares issued.
  • Price per Share: $0.05.
  • Gross Proceeds: $700,000.
  • Buyer: An insider of Kane Biotech Inc. (specific identity not disclosed).
  • Use of Proceeds: Working capital and general corporate purposes.
  • Hold Period: Shares subject to a four‑month + one‑day hold period from issuance date.
  • Closing Conditions: Closing remains subject to final approval by the TSX Venture Exchange.
  • Related‑Party Transaction Status: Deemed a “related party transaction” under MI 61‑101; exempt from formal valuation and minority‑approval requirements per Subsections 5.5(a) and 5.7(1)(a).

Notable Quotes

(No executive quotes were included in the release.)

Read the original news release →

More from Kane Biotech Inc.

May 28, 2026 · 17:05

Liquidity Secured, Revenue Collapse Raises Execution Concerns

Earnings May 26, 2026 · 07:25

Kane Biotech Raises Capital Amidst Revenue Collapse; Dilution Concerns Persist

Financings May 07, 2026 · 07:25

Kane Biotech Seeks $1M Amidst Revenue Slump and Cash Burn Concerns

Financings Apr 23, 2026 · 18:00

Kane Biotech Revenue Plummets as Restructuring Costs Mount; Cash Runway Tightens

Earnings Apr 16, 2026 · 16:57

Clinical Validation Continues as Commercial Restart Struggles to Generate Revenue

Other Apr 16, 2026 · 07:25

Clinical Validation Supports Commercial Restart, But Revenue Collapse and Dilution Risks Remain

Other